| Private Placement / Financing Transactions
Latigo Bio: The company raised $150 million of Series B venture funding in a deal led by Blue Owl Capital on March 17, 2025, putting the company’s pre-money valuation at $380 million. Access Biotechnology, Sanofi Ventures, UPMC Enterprises, Cormorant Asset Management, Foresite Capital, 5AM Ventures, Westlake Village BioPartners, Deep Track Capital, Kern Capital, Alexandria Venture Investments, Rock Springs Capital, Qatar Investment Authority, and other undisclosed investors also participated in the round. The company is an operator of a biotechnology business developing novel and non-opioid therapies for chronic pain.
Curevo Vaccine: The company raised $110 million of Series B venture funding in a deal led by Medicxi on March 17, 2025. GC Biopharma, Sanofi Ventures, OrbiMed, HBM Healthcare Investments, RA Capital Management, Adjuvant Capital and Janus Henderson Investors also participated in the round. The company is a developer of a clinical-stage adjuvanted subunit vaccine intended to improve efficacy and broaden immune response.
Arbor Biotechnologies: The company raised $73.9 million of Series C venture funding in a deal led by ARCH Venture Partners and TCG Crossover Management on March 18, 2025. Vertex Pharmaceuticals, Ally Bridge Group, Revelation Partners, Deep Track Capital, Partners Investment, Kerna Ventures, Aberdeen, Temasek Holdings, Piper Sandler, Surveyor Capital, T. Rowe Price Group, Qatar Investment Authority and ArrowMark Partners also participated in the round. The company is a developer of genomic tools (programmable DNA editors) designed to improve human health and sustainability.
Maxion Therapeutics: The company raised $72 million of Series A venture funding in a deal led by General Catalyst on March 17, 2025. Eli Lilly and Company, BGF, British Patient Capital, Monograph Capital, LifeArc Ventures and Solasta Ventures also participated in the round. The company is a developer of a novel platform designed to generate antibody-like therapeutics to solve ion channel and GPCR-driven diseases.
4C Medical: The company raised $175 million of Series D venture funding in a deal led by Boston Scientific on March 18, 2025. The company is a developer of a novel minimally invasive system designed for the treatment of mitral regurgitation.
Ampersand Biomedicines: The company raised $65 million of Series B venture funding from Eli Lilly and Company, Flagship Pioneering, and other undisclosed investors on March 19, 2025, putting the company’s pre-money valuation at $273 million. The company is a developer of programmable medicines and therapeutics designed to target disease sites precisely.
Cardiac Dimensions: The company raised $53 million of Series E venture funding in a deal led by Ally Bridge Group on March 20, 2025. Horizon 3 Healthcare, Claret Capital Partners, Lumira Ventures, M. H. Carnegie, Hostplus Superannuation Fund and other undisclosed investors also participated in the round. The company is a developer of novel interventional tools designed for the treatment of heart failure and related conditions of mitral valve regurgitation.
Proscia: The company raised $50 million through a combination of debt and Series B venture funding in a deal led by AI Capital Partners, Triangle Peak Partners and Insight Partners on March 19, 2025, putting the company’s pre-money valuation at $113 million. Avenue Capital Group, GPG Healthcare, Emerald Development Managers, Fusion Fund, Razor’s Edge Ventures, Interwoven Ventures and other undisclosed investors also participated in the round. The company is a developer of a digital pathology platform designed to enhance cancer diagnosis.
RegCell: The company raised $45.8 million of venture funding in a deal led by The University of Tokyo Edge Capital and Fast Track Initiative on March 18, 2025. Osaka University Venture Capital, Celadon Partners, Mitsubishi UFJ Capital, Kyoto University Innovation Capital and Japan Agency for Medical Research and Development also participated in the round. The company develops therapeutic technologies for autoimmune diseases, graft-versus-host disease, allergies and cancer through augmenting or suppressing immune responses by targeting regulatory T (Treg) cells.
Inspiren: The company raised $35 million of Series A venture funding in a deal led by Avenir Growth Capital on March 20, 2025. Story Ventures, Third Prime, Primary Venture Partners, and Studio VC also participated in the round. The company is an operator of an automated patient monitoring platform intended to reduce preventable harm to patients caused by human error.
Wheeler Bio: The company raised $35 million of Series A1 venture funding in a deal led by Alloy Therapeutics and Echo Investment Capital on March 20, 2025. Russell Westbrook Enterprises, Mitsubishi, Carnrite Ventures, and Germin8 Ventures also participated in the round. The company is a developer of a biomanufacturing service intended to accelerate the translation of therapeutic innovations into clinical impact.
Sibel Health: The company raised $30 million of Series C venture funding in a deal led by Drägerwerk and Steele Foundation for Hope on March 20, 2025. The company is a developer of clinical-grade health monitoring devices designed to measure heart rate, respiratory rate, skin temperature, body position, and activities of patients and pregnant mothers.
410 Medical: The company raised $25.7 million of Series B venture funding in a deal led by Hatteras Venture Partners on November 11, 2022. WakeMed Hospitals, OSF Ventures, Ballad Ventures, Orlando Health Ventures, Rex Health Ventures, Sarnova, Catalyst by Wellstar, Sea Purity Investments and University of Colorado also participated in the round. The company is a developer of a rapid infuser device designed to help critically ill patients requiring volume resuscitation.
Iksuda Therapeutics: The company closed on $15 million of a planned $25 million of venture funding from LigaChem Biosciences on March 21, 2025. The company is a developer of biological therapeutics designed to target difficult-to-treat cancers, including those resistant or refractory to current therapies.
Phantom Neuro: The company raised $12.1 million through a combination in Series A venture funding from undisclosed investors on March 17, 2025, putting the company’s pre-money valuation at $34.9 million. The company is an operator of a neurotechnology business intended to bridge the gap between modern-day robotics and individuals with limb differences.
BioPhy: The company raised $6.6 million of venture funding from undisclosed investors on March 20, 2025. The company is a developer of an artificial intelligence technology designed to optimize development decisions on therapeutics.
Modulo Bio: The company raised $4.8 million of venture funding from Alzheimers Drug Discovery Foundation on March 19, 2025. The company is a developer of digital biology mechanisms designed to accelerate the discovery of therapeutic targets harnessing autoimmunity.
Olio Labs: The company raised $4.5 million of venture funding in a deal led by Boom Capital Ventures and Overwater Ventures on March 19, 2025. Pioneer Fund, ZAKA VC, Scrum Ventures, SciFounders, Y Combinator and Olive Capital also participated in the round. The company is a developer of combination therapeutics designed to be effective and have less side effects.
machineMD: The company raised CHF 2.8 million of Series A venture funding in a deal led by Topcon Healthcare on March 18, 2025, putting the company’s pre-money valuation at CHF 9 million. The company is a developer of an automated medical device designed to improve the measurement of brain function.
BioClec: The company raised an undisclosed amount of venture funding from Sofinnova Partners on March 18, 2025. The company is developing precision therapies for Alzheimer’s disease.
Forth Therapeutics: The company raised an undisclosed amount of venture funding from Old College Capital and Sofinnova Partners on March 18, 2025. The company is a developer of precision treatments for fibrotic disease.
|
